CompletedPhase 2NCT01738035
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calliditas Therapeutics AB
- Principal Investigator
- Bengt Fellström, MD, PhD, M.DProfessor of Medicine Department of Medical Sciences, Renal Medicine Uppsala University Hospital, Sweden
- Intervention
- NEFECON(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2015
Study locations (30)
- University Hospital of Antwerp, Antwerp, Belgium
- Imelda Hospital, Bonheiden, Belgium
- Ghent University Hospital, Ghent, Belgium
- University Hospitals Leuven, Leuven, Belgium
- Heilig Hartziekenhuis Roeselare-Menen, Roeselare, Belgium
- University Hospital, Olomouc, Czechia
- Charles University & General University Hospital, Prague, Czechia
- Institut klinické a experimentální medicíny, Prague, Czechia
- Rigshospitalet, Copenhagen, Denmark
- Herlev Hospital, Herlev, Denmark
- Odense University Hospital, Odense, Denmark
- Helsinki University Central Hospital, Helsinki, Finland
- Tampere University Hospital, Tampere, Finland
- Turku University Central Hospital, Turku, Finland
- RWTH Aachen, Aachen, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01738035 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07571746A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseAstraZeneca
- RECRUITINGPHASE2NCT07146906A Study to Assess the Effects of Zigakibart on IgA Nephropathy.Novartis Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07375758A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.Beijing Mabworks Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University